PR-39

PR-39 rapidly enters bacteria via a SbmA-dependent uptake mechanism without causing membrane lysis. Once intracellular, it stops DNA and protein synthesis by binding to specific proteins including DnaA, FtsH, and 30S ribosomal subunit proteins. Bacteria treated with PR-39 form elongated filaments with inhibited septum formation, eventually dying from metabolic failure. This non-lytic mechanism may reduce selection pressure for resistance compared to membrane-disrupting AMPs.

PR-39 promotes angiogenesis through a novel mechanism: it inhibits ubiquitin-proteasome degradation of HIF-1alpha, the master transcription factor for hypoxia responses. Under normoxic conditions where HIF-1alpha would normally be degraded, PR-39 allows HIF-1alpha to accumulate, driving expression of VEGF, angiopoietins, and other pro-angiogenic factors. This property accelerates wound vascularization and healing in animal models.

PR-39 accelerates cutaneous wound healing in animal models by promoting granulation tissue vascularization through HIF-1alpha stabilization. Topical PR-39 application reduces wound closure time and improves tissue quality in diabetic wound models. The angiogenic mechanism distinguishes PR-39 from other wound-healing peptides like BPC-157 and thymosin-beta-4 that act through different pathways.

Adeno-associated virus delivery of PR-39 to myocardium protects against ischemia-reperfusion injury through HIF-1alpha stabilization and subsequent VEGF upregulation. Cardiac PR-39 expression improves collateral vessel formation in chronic myocardial ischemia models. These findings suggest potential for cardiovascular applications, though delivery challenges remain.